Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hargrove

Showing results (71-80 of 72) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 72 results.
Bioorganic & Medicinal Chemistry Letters|September 21, 2010
Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesityRichard L Elliott, Kimberly O Cameron, Janice E Chin, et al.
Archives of Toxicology|October 4, 2024
Minimum information for reporting on the TEER (trans-epithelial/endothelial electrical resistance) assay (MIRTA)Monita Sharma, Erin Huber, Emma Arnesdotter, et al.
Pageof 8

Showing results (71-80 of 72) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 72 results.
Bioorganic & Medicinal Chemistry Letters|September 21, 2010
Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesityRichard L Elliott, Kimberly O Cameron, Janice E Chin, et al.
Archives of Toxicology|October 4, 2024
Minimum information for reporting on the TEER (trans-epithelial/endothelial electrical resistance) assay (MIRTA)Monita Sharma, Erin Huber, Emma Arnesdotter, et al.
Pageof 8